FDA Expands Leniolisib Approval to Younger Children with APDS
The FDA approved leniolisib (Joenja) on September 11 for children aged 4 through 11 weighing at least 27 kg with activated…
Curated clinical updates, research breakdowns, and expert perspectives focusing on specific pathways of childhood immune development and pathology.
The FDA approved leniolisib (Joenja) on September 11 for children aged 4 through 11 weighing at least 27 kg with activated…
A new systematic review and meta-analysis published in JAMA Pediatrics confirms what the original pivotal trials hinted at: the…
The NIH announcement frames the work as a safety and efficacy signal: peanut-tolerant participants tolerated higher allergen…
The American Academy of Pediatrics has tightened its clinical guidance on RSV immunoprophylaxis, expanding the qualifying…
As the National Cancer Institute reports in a recent feature on benefits of NCI-supported rare disease research, one high-grade…
According to the American College of Rheumatology (ACR), its 2026 Rheumatic Disease Awareness Month campaign, “Little Joints, Big…
The FDA approved ustekinumab (Stelara) on August 28 for moderately to severely active ulcerative colitis in pediatric patients…
According to Medscape, the specialty of pediatric dermatology is being positioned as "a rewarding career path in a critical time…
The FDA has approved Imaavy (nipocalimab-aahu) for warm autoimmune hemolytic anemia in adults and adolescents aged 12 years and…
A study surfaced on ResearchGate this week — published in Allergy, Asthma & Clinical Immunology — that addresses a question I…
The FDA's Center for Biologics Evaluation and Research has released Version 3 of its standard operating procedure for applying…
According to Medical Dialogues' coverage of the ZIPS-2 randomized clinical trial published in JAMA, daily 20-mg oral zinc sulfate…
A new peer-reviewed study from Trinity College Dublin, published in the Journal of the American Academy of Dermatology, reports…
Researchers at St. Jude Children's Research Hospital report that deleting the Regnase-1 gene from B7-H3-targeted CAR T cells…
A structured expert-elicitation study distributed through JoVE Visualize and Pediatric Allergy and Immunology has done something…
According to a recent announcement from Children's Health Research Institute (CHRI), researchers at London Health Sciences Centre…
A longitudinal study of 1,736 intravenous immunoglobulin infusions in 70 pediatric patients with inborn errors of immunity…
Announced by the Department of Health and Human Services on August 21, the RFI signals an evaluation of how recommendations are…
The European Medicines Agency has issued a positive opinion on an orphan designation for an autologous CD34+ stem cell gene…
The Nature study frames citywide rapid WGS implementation as a system-level intervention rather than a single-center pilot, which…
The data supporting home subcutaneous immunoglobulin therapy in pediatric primary immunodeficiency is no longer in dispute…
When we discuss the barriers to pediatric clinical trial enrollment, the conversation often centers on eligibility criteria or…
According to McGill University Health e-News, a McGill-led study has found that T cells can sense the stiffness of the tissue…
A new case report published in Frontiers in Immunology describes a pediatric patient carrying a previously unreported c.841G>C…
The Children's Health Research Institute in London, Ontario, has opened what it claims is Canada's first pediatric laboratory…
The FDA has cleared the first gene therapy for Glycogen Storage Disease Type Ia (GSDIa), approving Genglycos (pariglasgene…
Medical Xpress is flagging a recent study that, in its framing, sets a new standard for pediatric research — and that framing…
According to a study indexed on PubMed, researchers applied bulk transcriptomics to peripheral blood mononuclear cells from…
Per a recent Cureus review, the field of in vivo base editing for neonatal inborn errors of metabolism has moved from bench…
According to a PubMed-indexed analysis of the OPIA trial, baseline functional profiles of peanut-reactive T cells may serve as…
In my experience running pediatric immunodeficiency cohorts, this is the single most common dosing question I get from both…
For families considering a pediatric gene therapy clinical trial, the most difficult part is often not finding a study. It is…
The FDA reports an approval rate of approximately 99% for submitted Expanded Access Program applications, with more than 75%…
A pediatric hematopoietic stem cell transplant (HSCT) rarely begins on the day the cells are infused. By the time the product…
A denial of pediatric biologic therapy is rarely a simple statement that a child is “not eligible” for treatment. More often, it…
Intravenous and subcutaneous immunoglobulin replacement constitute the two established administration routes for pediatric…
The deferral question lands on my desk roughly once a week. A family has a child on monthly IVIG for a primary antibody…
The 2017 FDA approval of tisagenlecleucel for pediatric and young adult relapsed/refractory B-cell ALL was supposed to be the…
The Forbes piece, dated August 11, landed alongside a cluster of practical pediatric guidance updates that underscore exactly why…
In July 2026, the BMJ published the SPIRIT-C 2026 and CONSORT-C 2026 extensions — a set of new reporting expectations intended to…